News Articles

ResMed to Host an Investor Meeting on April 4, 2019 SAN DIEGO -Sunday 24 March 2019

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD) today announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software. Additional information...

ResMed Acquires HB Healthcare to Help Millions of Koreans Living with Sleep Apnea, Other Respiratory Conditions -Saturday 9 March 2019

(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD), a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, today announced that is has completed the acquisition of HB Healthcare (HBH) to help millions of South Koreans living with sleep apnea, chronic...

ResMed and Fisher & Paykel Healthcare Announce Settlement of Global Patent Infringement Litigation -Thursday 21 February 2019  

(BUSINESS WIRE) -- ResMed (NYSE: RMD, ASX: RMD), and Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today announced an agreement to settle all outstanding patent infringement disputes between the companies in all venues around the world. The settlement involves no payment or admission of...

ResMed’s First Top-of-Head CPAP Mask, AirFit N30i, Now Available across U.S. -Tuesday 22 January 2019  

(BUSINESS WIRE) -- ResMed (NYSE: RMD, ASX: RMD), today introduced AirFit N30i, its first top-of-head-connected nasal CPAP mask, across the United States, with a newly designed nasal cradle cushion that sits just under the wearer’s nose. The top-of-head connection keeps tubing out of the...

Mobi Is Here: ResMed’s First Portable Oxygen Device Now Widely Available in the U.S. -Thursday 10 January 2019  

(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD), a leader in respiratory care medical devices and out-of-hospital care software, today announced that its premier portable oxygen concentrator, Mobi, is now widely available in the United States. Mobi offers an optimal balance of oxygen delivery,...

ResMed Completes $225 Million Acquisition of Propeller Health -Wednesday 9 January 2019  

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has completed its acquisition of Propeller Health, a digital therapeutics company providing connected health...

ResMed to Acquire Propeller Health, a Leader in COPD and Asthma Connected Health Solutions, for $225 Million -Wednesday 5 December 2018  

(BUSINESS WIRE) -- ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has entered a definitive agreement to acquire Propeller Health, a digital therapeutics company providing connected...

ResMed Elects Harjit Gill to Its Board of Directors -Wednesday 21 November 2018  

(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service business solutions, today announced it has elected experienced consumer and healthcare executive Harjit Gill to its Board of Directors. Ms. Gill was elected by...

ResMed Completes Acquisition of MatrixCare -Thursday 15 November 2018  

Establishes ResMed as a leader in out-of-hospital software-as-a-service offerings Expands ResMed’s SaaS offerings into additional care settings, including skilled nursing and senior living Purchase price $750 million, accretive to non-GAAP gross margin and non-GAAP diluted earnings per...

ResMed to Acquire MatrixCare, Expands Out-of-Hospital SaaS Portfolio into Long-Term Care Settings -Tuesday 6 November 2018  

Expands ResMed’s out-of-hospital software portfolio into skilled nursing and senior living verticals Enhances ResMed’s ability to improve patient transitions of care and provider efficiencies Purchase price $750 million, accretive to non-GAAP gross margin and non-GAAP diluted earnings...

ResMed Wins German Patent Infringement Case Against Fisher & Paykel -Tuesday 23 October 2018

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical company and innovator in sleep apnea and respiratory care, today announced the results of a court and patent office ruling in Germany in ResMed’s favor. A trial court ruling from the Munich District...

AirFit F30, ResMed’s First Minimal-Contact Full Face CPAP Mask, Now Available in the U.S., Canada -Tuesday 16 October 2018  

(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD) today announced the availability of its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps sleep apnea patients reduce facial marks, wear glasses in bed and curl up closer to their...

175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis -Wednesday 19 September 2018

(BUSINESS WIRE)-- Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researchers estimate 90 million Europeans have moderate to severe sleep...

ResMed Introduces Its First Minimal-contact Full Face CPAP Mask, AirFit F30 -Friday 14 September 2018  

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD) today introduced its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps users reduce facial marks, wear glasses in bed and curl up closer to their bed partner. Unlike most...

ResMed Files Patent Infringement Action against Fisher & Paykel -Saturday 1 September 2018

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical device company and innovator in sleep apnea and respiratory care, today filed a petition with the United States International Trade Commission to stop the infringement of its patented technology by New...

ResMed’s Astral Life Support Ventilator Now Has AutoEPAP in U.S. -Tuesday 28 August 2018  

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD), a global leader in cloud-connected respiratory care devices, today announced key upgrades to its Astral life support ventilators, including Optional AutoEPAP in iVAPS for U.S. patients, a high-demand therapy option. What is...

ResMed, Verily to Form Joint Venture to Help Reach Millions of Untreated Sleep Apnea Sufferers -Thursday 12 July 2018  

(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD), a global leader in sleep apnea treatment and connected health solutions, and Verily, an Alphabet company, today announced their agreement to form a new joint venture. Combining ResMed’s expertise in sleep apnea and Verily’s advanced health...

New ResMed-sponsored Study Shows Switching to Bilevel PAP Saves 56% of Patients from Therapy Termination -Tuesday 5 June 2018

(BUSINESS WIRE)-- A new study reveals that shifting patients who are struggling with adherence to positive airway pressure (PAP) therapy to a more advanced bilevel device in the first 90 days of treatment is an effective tool for achieving adherence in well more than half of such cases. This...

ResMed to Acquire HEALTHCAREfirst, a Cloud-based Software and Services Provider for Home Health and Hospice Agencies -Wednesday 30 May 2018  

(BUSINESS WIRE) -- ResMed (NYSE:RMD, ASX:RMD), a global leader in connected healthcare solutions, today announced it has entered into a definitive agreement to acquire privately held HEALTHCAREfirst, a provider of software solutions and services for home health and hospice...

ResMed Studies Show Remote Monitoring and Automated Resupply Improve Adherence to PAP Therapy -Wednesday 23 May 2018

(BUSINESS WIRE)-- Remote patient monitoring and resupply programs have been shown to improve patient adherence to positive airway pressure (PAP) therapy, according to two separate studies presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference. Remote...

Results 1-20 of 24